Arvinas, Inc. announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company. Dr. Taylor and Dr. Cacace will assume these new roles effective immediately and report to John Houston, Ph.D., Chairperson, President and Chief Executive Officer. Dr. Taylor joined Arvinas in 2016 as Vice President of Pharmacology and Translational Medicine and has held positions of increasing responsibility, including serving as Chief Scientific Officer of the company since early 2019.

Prior to Arvinas, Dr. Taylor had long tenures at Bayer and Pfizer, where he held leadership roles in Oncology Research and Development, respectively. As President of R&D, Dr. Taylor will provide strategic input across the company?s broad pipeline, from early research efforts to multiple development programs in oncology and neuroscience. Dr. Taylor will continue to be an important connection to outside stakeholders, including thought leaders, strategic partners, and investors, and will also chair the Company?s Scientific Advisory Board, with whom he?s worked since joining Arvinas.

Dr. Cacace joined Arvinas in 2018 as Vice President of Neuroscience and Platform Biology, bringing over two decades of drug discovery experience in neuroscience and oncology research across modalities. She most recently served as Senior Vice President, Neuroscience and Platform Biology. Her prior experience at Pfizer focused on oncology antibody drug discovery efforts to deliver an anti-angiogenic clinical candidate.

While at Bristol-Myers Squibb, in positions of increasing responsibility in research, and as head of biology at Fulcrum Therapeutics, she built innovative pipelines, grew talented scientific teams, delivered multiple clinical candidates, and guided the development of translational biomarkers to enable clinical development programs. Over the past six years, together with the Arvinas team, Dr. Cacace has led the continuous evolution of Arvinas? powerful PROTAC® Discovery Engine to employ new E3 ligases and cross the blood-brain barrier for multiple neurologic disease targets, including the delivery of PROTAC® LRRK2 degrader ARV-102 into ongoing clinical trials.